Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, USA.
Curr Opin Hematol. 2010 Jul;17(4):276-80. doi: 10.1097/MOH.0b013e328339f2ee.
Induced pluripotent stem cell (iPSC) technology, which uses defined transcription factors to reprogram somatic cells to become pluripotent cells, offers a significant technical simplicity and enables generation of patient-specific pluripotent stem cells with reduced ethical concerns. This review will focus on recent progresses in understanding of iPSCs and improved methods of generating iPSCs.
Whereas iPSCs generated from a variety of cell sources were found to be nearly identical functionally to embryonic stem cells, some differences were also identified and remain to be characterized. Meanwhile, new methods of generating iPSCs with minimal or no exogenous genetic modifications to cells have advanced rapidly.
iPSC technology provides unprecedented opportunities in biomedical research and regenerative medicine. However, there remain a great deal to learn about iPSC safety, the reprogramming mechanisms, and better ways to direct a specific reprogramming process. The iPSC field will flourish on its mechanistic studies, iPSC-based disease modeling, and identification of new small molecules that modulate reprogramming.
诱导多能干细胞(iPSC)技术使用定义的转录因子将体细胞重编程为多能细胞,具有显著的技术简单性,并能够生成减少伦理问题的患者特异性多能干细胞。本综述将重点介绍 iPSC 的最新研究进展和生成 iPSC 的改进方法。
尽管从多种细胞来源生成的 iPSC 在功能上几乎与胚胎干细胞相同,但也发现了一些差异,这些差异仍有待进一步表征。同时,新的生成 iPSC 的方法也迅速发展起来,这些方法对细胞的外源性遗传修饰最小或没有。
iPSC 技术为生物医学研究和再生医学提供了前所未有的机会。然而,关于 iPSC 的安全性、重编程机制以及更好地指导特定重编程过程的方法,仍有很多需要了解。iPSC 领域将在其机制研究、基于 iPSC 的疾病建模以及鉴定新的调节重编程的小分子方面蓬勃发展。